We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+21.28%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$2.03B
AUM Growth
+$384M
Cap. Flow
+$76.6M
Cap. Flow %
3.78%
Top 10 Hldgs %
49.69%
Holding
79
New
15
Increased
27
Reduced
15
Closed
14
Avg Time Held Equity + Options
1.1 years
Top 10 Avg Time Held Equity + Options
1.2 years
Top 20 Avg Time Held Equity + Options
1.1 years
Avg Time Held Equity only
1.1 years
Top 10 Avg Time Held Equity only
1.2 years
Top 20 Avg Time Held Equity only
1.1 years

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$71M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$60.3M
3
ALDR
Alder Biopharmaceuticals
ALDR
+$44.3M
4
NITE icon
Nightstar Therapeutics plc American Depositary Shares
NITE
+$38.2M
5
INSM icon
Insmed
INSM
+$37.7M

Top Sells

Rank Stock Value
1
JUNO
Juno Therapeutics, Inc.
JUNO
+$66.3M
2
ELV icon
Elevance Health
ELV
+$43.6M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$35M
4
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
+$32M
5
PEN icon
Penumbra
PEN
+$31.5M

Sector Composition

Rank Sector Weight
1 Healthcare 94.27%
2 Financials 3.41%
3 Miscellaneous 1.69%
4 Communication Services 0.62%
5 Energy 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
VRTX icon
26
Vertex Pharmaceuticals
VRTX
$129B
$28.7M 1.42%
189,008
+44,600
+31% +$6.71M
2017 Q2
1 quarter
IRTC icon
27
iRhythm Holdings
IRTC
$3.6B
$28.6M 1.41%
552,041
+75,700
+16% +$3.43M
2017 Q2
1 quarter
XNCR icon
28
Xencor
XNCR
$1.78B
$27.5M 1.36%
1,200,294
+12,800
+1% +$284K
2016 Q4
3 quarters
LJPC
29
DELISTED
La Jolla Pharmaceutical Company
LJPC
$25.2M 1.24%
723,330
+10,050
+1% +$323K
2017 Q1
2 quarters
EPZM
30
DELISTED
Epizyme, Inc
EPZM
$23.1M 1.14%
+1,210,000
New +$18.5M
2017 Q3
0 quarters
CMRX icon
31
DELISTED
Chimerix, Inc.
CMRX
$22.2M 1.09%
4,225,575
+18,000
+0.4% +$88.6K
2016 Q2
5 quarters
DPLO
32
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
$19.8M 0.98%
+957,155
New +$16.2M
2017 Q3
0 quarters
NVTA
33
DELISTED
Invitae Corporation
NVTA
$19.8M 0.98%
2,112,240
+1,300,000
+160% +$12.3M
2015 Q1
10 quarters
BSX icon
34
Boston Scientific
BSX
$64B
$17.6M 0.87%
603,493
-491,490
-45% -$13.6M
2015 Q4
7 quarters
CBIO icon
35
Crescent Biopharma
CBIO
$464M
$17M 0.84%
12,141
+6,145
+102% +$7.21M
2017 Q2
1 quarter
MEDP icon
36
Medpace
MEDP
$17.5B
$15.9M 0.79%
499,640
+274,600
+122% +$8.39M
2017 Q2
1 quarter
AMED icon
37
DELISTED
Amedisys
AMED
$15.9M 0.78%
283,648
+280,292
+8,352% +$14.8M
2017 Q1
2 quarters
JNCE
38
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$14.9M 0.73%
955,598
-182,772
-16% -$2.58M
2017 Q1
2 quarters
SYNH
39
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$14M 0.69%
267,918
-573,500
-68% -$32M
2017 Q1
2 quarters
CBAY icon
40
DELISTED
Cymabay Therapeutics
CBAY
$13.3M 0.65%
+1,647,100
New +$11.1M
2017 Q3
0 quarters
LUMO icon
41
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$12.7M 0.63%
+138,744
New +$10.6M
2017 Q3
0 quarters
MODN icon
42
DELISTED
MODEL N, INC.
MODN
$12.5M 0.62%
838,914
-19,400
-2% -$259K
2013 Q4
15 quarters
DCPH icon
43
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$12M 0.59%
+722,880
New +$13.2M
2017 Q3
0 quarters
ATYR icon
44
aTyr Pharma
ATYR
$18M
$9.53M 0.47%
+134,771
New +$6.24M
2017 Q3
0 quarters
SYRS icon
45
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$9.44M 0.47%
64,142
-33,184
-34% -$6.24M
2016 Q2
5 quarters
CASC
46
DELISTED
Cascadian Therapeutics, Inc.
CASC
$8.06M 0.4%
1,969,969
-1,766,025
-47% -$6.76M
2017 Q1
2 quarters
PRQR icon
47
ProQR Therapeutics
PRQR
$205M
$7.77M 0.38%
1,602,975
+6,700
+0.4% +$34.8K
2014 Q3
12 quarters
TFX icon
48
Teleflex
TFX
$5.43B
$7.59M 0.37%
+31,365
New +$6.82M
2017 Q3
0 quarters
CTMX icon
49
CytomX Therapeutics
CTMX
$525M
$6.95M 0.34%
382,271
-316,121
-45% -$4.93M
2015 Q4
7 quarters
PETQ icon
50
DELISTED
PetIQ, Inc. Class A Common Stock
PETQ
$6.68M 0.33%
+246,743
New +$5.97M
2017 Q3
0 quarters
1
2
3 4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q3 2017 Portfolio in Review

As of Q3 2017, Redmile Group held 79 positions worth $2.03B, up 23% from $1.64B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Redmile Group deployed $76.6M of net new capital in Q3 2017, opening 15 new positions and adding to 27 existing holdings. Its largest new stake was AstraZeneca: 1,123,150 shares worth $76.1M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Financials and Miscellaneous.

On the sell side, the largest reduction was Syneos Health, Inc. Class A Common Stock, an estimated $32M trimmed.

  • Redmile Group's largest Q3 2017 buy was AstraZeneca: 1,123,150 shares worth $76.1M.
  • Redmile Group added most to Seagen Inc. Common Stock in Q3 2017, an estimated $60.3M increase.
  • Redmile Group's biggest Q3 2017 reduction was Syneos Health, Inc. Class A Common Stock, cutting an estimated $32M.
  • Redmile Group fully exited Juno Therapeutics, Inc. in Q3 2017, selling an estimated $66.3M.
  • Redmile Group's ten largest holdings make up 50% of its $2.03B portfolio in Q3 2017.
  • Redmile Group opened 15 new positions and closed 14 in Q3 2017.
  • Redmile Group's portfolio value rose 23% quarter-over-quarter to $2.03B.

Based on Redmile Group's 13F filing for Q3 2017, filed 14 Nov 2017.